Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-Kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim
Received September 15, 2023 Accepted November 1, 2023 Published online January 10, 2024
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
Single-cell RNA sequencing has become a powerful and essential tool for delineating cellular diversity in normal tissues and alterations in disease states. For certain cell types and conditions, there are difficulties in isolating intact cells for transcriptome profiling due to their fragility, large size, tight interconnections, and other factors. Single-nucleus RNA sequencing (snRNA-seq) is an alternative or complementary approach for cells that are difficult to isolate. In this review, we will provide an overview of the experimental and analysis steps of snRNA-seq to understand the methods and characteristics of general and tissue-specific snRNA-seq data. Knowing the advantages and limitations of snRNA-seq will increase its use and improve the biological interpretation of the data generated using this technique.
Citations
Citations to this article as recorded by
Mapping the cellular landscape of Atlantic salmon head kidney by single cell and single nucleus transcriptomics Adriana M.S. Andresen, Richard S. Taylor, Unni Grimholt, Rose Ruiz Daniels, Jianxuan Sun, Ross Dobie, Neil C. Henderson, Samuel A.M. Martin, Daniel J. Macqueen, Johanna H. Fosse Fish & Shellfish Immunology.2024; 146: 109357. CrossRef
Impaired cortical neuronal homeostasis and cognition after diffuse traumatic brain injury are dependent on microglia and type I interferon responses Jonathan M. Packer, Chelsea E. Bray, Nicolas B. Beckman, Lynde M. Wangler, Amara C. Davis, Ethan J. Goodman, Nathaniel E. Klingele, Jonathan P. Godbout Glia.2024; 72(2): 300. CrossRef
Adipose tissue macrophage heterogeneity in the single-cell genomics era Haneul Kang, Jongsoon Lee Molecules and Cells.2024; 47(2): 100031. CrossRef
Single-cell and spatially resolved transcriptomics for liver biology Ping Lin, Xi Yan, Siyu Jing, Yanhong Wu, Yiran Shan, Wenbo Guo, Jin Gu, Yu Li, Haibing Zhang, Hong Li Hepatology.2023;[Epub] CrossRef
Integrated analysis of single-cell and bulk RNA-seq establishes a novel signature for prediction in gastric cancer Fei Wen, Xin Guan, Hai-Xia Qu, Xiang-Jun Jiang World Journal of Gastrointestinal Oncology.2023; 15(7): 1215. CrossRef
Placental single cell transcriptomics: Opportunities for endocrine disrupting chemical toxicology Elana R. Elkin, Kyle A. Campbell, Samantha Lapehn, Sean M. Harris, Vasantha Padmanabhan, Kelly M. Bakulski, Alison G. Paquette Molecular and Cellular Endocrinology.2023; 578: 112066. CrossRef
Analyzing alternative splicing in Alzheimer’s disease postmortem brain: a cell-level perspective Mohammad-Erfan Farhadieh, Kamran Ghaedi Frontiers in Molecular Neuroscience.2023;[Epub] CrossRef
Single-nucleus transcriptome inventory of giant panda reveals cellular basis for fitness optimization under low metabolism Shangchen Yang, Tianming Lan, Rongping Wei, Ling Zhang, Lin Lin, Hanyu Du, Yunting Huang, Guiquan Zhang, Shan Huang, Minhui Shi, Chengdong Wang, Qing Wang, Rengui Li, Lei Han, Dan Tang, Haimeng Li, Hemin Zhang, Jie Cui, Haorong Lu, Jinrong Huang, Yonglun BMC Biology.2023;[Epub] CrossRef
Single-cell transcriptomics in thyroid eye disease Sofia Ahsanuddin, Albert Y. Wu Taiwan Journal of Ophthalmology.2023;[Epub] CrossRef
Traditionally, diagnostic pathology uses histology representing structural alterations in a disease’s cells and tissues. In many cases, however, it is supplemented by other morphology-based methods such as immunohistochemistry and fluorescent in situ hybridization. Single-cell RNA sequencing (scRNA-seq) is one of the strategies that may help tackle the heterogeneous cells in a disease, but it does not usually provide histologic information. Spatial sequencing is designed to assign cell types, subtypes, or states according to the mRNA expression on a histological section by RNA sequencing. It can provide mRNA expressions not only of diseased cells, such as cancer cells but also of stromal cells, such as immune cells, fibroblasts, and vascular cells. In this review, we studied current methods of spatial transcriptome sequencing based on their technical backgrounds, tissue preparation, and analytic procedures. With the pathology examples, useful recommendations for pathologists who are just getting started to use spatial sequencing analysis in research are provided here. In addition, leveraging spatial sequencing by integration with scRNA-seq is reviewed. With the advantages of simultaneous histologic and single-cell information, spatial sequencing may give a molecular basis for pathological diagnosis, improve our understanding of diseases, and have potential clinical applications in prognostics and diagnostic pathology.
Citations
Citations to this article as recorded by
Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine Pankaj Ahluwalia, Kalyani Ballur, Tiffanie Leeman, Ashutosh Vashisht, Harmanpreet Singh, Nivin Omar, Ashis K. Mondal, Kumar Vaibhav, Babak Baban, Ravindra Kolhe Cancers.2024; 16(3): 480. CrossRef
Potential therapeutic targets for hypotension in duchenne muscular dystrophy Harshi Saxena, Neal L. Weintraub, Yaoliang Tang Medical Hypotheses.2024; 185: 111318. CrossRef
A comparative analysis of single-cell transcriptomic technologies in plants and animals Vamsidhar Reddy Netla, Harshraj Shinde, Gulshan Kumar, Ambika Dudhate, Jong Chan Hong, Ulhas Sopanrao Kadam Current Plant Biology.2023; 35-36: 100289. CrossRef
Fibroblasts – the cellular choreographers of wound healing Samuel Knoedler, Sonja Broichhausen, Ruiji Guo, Ruoxuan Dai, Leonard Knoedler, Martin Kauke-Navarro, Fortunay Diatta, Bohdan Pomahac, Hans-Guenther Machens, Dongsheng Jiang, Yuval Rinkevich Frontiers in Immunology.2023;[Epub] CrossRef
Background Activating mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) are predictive biomarkers for response to EGFR–tyrosine kinase inhibitor (TKI) therapy in lung adenocarcinoma (LUAD). Here, we characterized the clinicopathologic features associated with EGFR mutations via peptide nucleic acid clamping-assisted fluorescence melting curve analysis (PANAMutyper) and evaluated the feasibility of targeted deep sequencing for detecting the mutations.
Methods We examined EGFR mutations in exons 18 through 21 for 2,088 LUADs from July 2017 to April 2020 using PANAMutyper. Of these, we performed targeted deep sequencing in 73 patients and evaluated EGFR-mutation status and TKI clinical response.
Results EGFR mutation was identified in 55.7% of LUADs by PANAMutyper, with mutation rates higher in females (69.3%) and never smokers (67.1%) and highest in the age range of 50 to 59 years (64.9%). For the 73 patients evaluated using both methods, next-generation sequencing (NGS) identified EGFR mutation–positive results in 14 of 61 patients (23.0%) who were EGFR-negative according to PANAMutyper testing. Of the 10 patients reportedly harboring a sensitizing mutation according to NGS, seven received TKI treatment, with all showing partial response or stable disease. In the 12 PANAMutyper-positive cases, NGS identified two additional mutations in exon 18, whereas a discordant negative result was observed in two cases.
Conclusions Although PANAMutyper identified high frequencies of EGFR mutations, targeted deep sequencing revealed additional uncommon EGFR mutations. These findings suggested that appropriate use of NGS may benefit LUAD patients with otherwise negative screening test results.
Lymphocyte-rich effusions represent benign reactive process or neoplastic condition. Involvement of lymphoproliferative disease in body cavity is not uncommon, and it often causes diagnostic challenge. In this review, we suggest a practical diagnostic approach toward lymphocyte-rich effusions, share representative cases, and discuss the utility of ancillary tests. Cytomorphologic features favoring neoplastic condition include high cellularity, cellular atypia/pleomorphism, monomorphic cell population, and frequent apoptosis, whereas lack of atypia, polymorphic cell population, and predominance of small T cells usually represent benign reactive process. Involvement of non-hematolymphoid malignant cells in body fluid should be ruled out first, followed by categorization of the samples into either small/medium-sized cell dominant or large-sized cell dominant fluid. Small/medium-sized cell dominant effusions require ancillary tests when either cellular atypia or history/clinical suspicion of lymphoproliferative disease is present. Large-sized cell dominant effusions usually suggest neoplastic condition, however, in the settings of initial presentation or low overall cellularity, ancillary studies are helpful for more clarification. Ancillary tests including immunocytochemistry, in situ hybridization, clonality test, and next-generation sequencing can be performed using cytologic preparations. Throughout the diagnostic process, proper review of clinical history, cytomorphologic examination, and application of adequate ancillary tests are key elements for successful diagnosis.
Citations
Citations to this article as recorded by
The urgency of Burkitt lymphoma diagnosis in fluid cytology—A tertiary care experience Soundarya Ravi, Anu K. Devi, Prabhu Manivannan, Debasis Gochhait, Rakhee Kar, Neelaiah Siddaraju Cytopathology.2024; 35(2): 275. CrossRef
Immunocytochemistry on frozen-embedded cell block for the diagnosis of hematolymphoid cytology specimen: a straightforward alternative to the conventional cell block Youjeong Seo, Sanzida Alam Prome, Lucia Kim, Jee Young Han, Joon Mee Kim, Suk Jin Choi Journal of Hematopathology.2024; 17(1): 1. CrossRef
Lymphoma presenting as the first finding in pleural fluid cytology: A rare cytologic presentation Kafil Akhtar, Gowthami Nagendhran, Anjum Ara, Masheera Akhtar IP Archives of Cytology and Histopathology Research.2024; 8(4): 250. CrossRef
Hemangioblastoma (HB) is a rare benign tumor that most commonly occurs in the cerebellum. HB is composed of neoplastic stromal cells and abundant small vessels. However, the exact origin of stromal cells is controversial. Extraneural HBs have been reported in a small series, and peripheral HBs arising in the adrenal gland are extremely rare. Herein, we report a case of sporadic adrenal HB in a 54-year-old woman. The tumor was a well-circumscribed, yellow mass measuring 4.2 cm in diameter. Histologically, the tumor was composed of small blood vessels and vacuolated stromal cells with clear cytoplasm. On immunohistochemical stain, the stromal cells were positive for S-100 protein, neuron-specific enolase, and synaptophysin. The tumor did not reveal mutation of VHL alleles. We herein present a case of HB of the adrenal gland and review of the literature.
Microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) status has been approved as a tissue-agnostic biomarker for immune checkpoint inhibitor therapy in patients with solid tumors. We report the case of an MSI-H/dMMR diffuse large B-cell lymphoma (DLBCL) identified by targeted gene sequencing (TGS). A 90-year-old female who presented with vaginal bleeding and a large mass in the upper vagina was diagnosed with germinal center-B-cell-like DLBCL, which recurred at the uterine cervix at 9 months after chemotherapy. Based on TGS of 121 lymphoma-related genes and the LymphGen algorithm, the tumor was classified genetically as DLBCL of EZB subtype. Mutations in multiple genes, including frequent frameshift mutations, were detected by TGS and further suggested MSI. The MSI-H/dMMR and loss of MLH1 and PMS2 expression were determined in MSI-fragment analysis, MSI real-time polymerase chain reaction, and immunohistochemical tests. This case demonstrates the potential diagnostic and therapeutic utility of lymphoma panel sequencing for DLBCL with MSI-H/dMMR.
Citations
Citations to this article as recorded by
Chimeric and mutant CARD9 constructs enable analyses of conserved and diverged autoinhibition mechanisms in the CARD‐CC protein family Jens Staal, Yasmine Driege, Femke Van Gaever, Jill Steels, Rudi Beyaert The FEBS Journal.2024; 291(6): 1220. CrossRef
PD-L1+diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquiredPMS2mutation Andrew W. Allbee, James Gerson, Guang Yang, Adam Bagg Molecular Case Studies.2023; 9(4): a006318. CrossRef
Background Langerhans cell histiocytosis (LCH) is more common in children than adults and involves many organs. In children, the BRAF V600E mutation is associated with recurrent and high-risk LCH.
Methods We collected paraffin blocks of 94 pediatric LCH patients to detect BRAF V600E mutation by sequencing. The relationship between BRAF V600E status and clinicopathological parameters were also critically analyzed.
Results BRAF V600E mutation exon 15 was detected in 45 cases (47.9%). Multiple systems LCH showed a significantly higher BRAF V600E mutation rate than a single system (p=.001). No statistical significance was evident for other clinical characteristics such as age, sex, location, risk organs involvement, and CD1a expression.
Conclusions In Vietnamese LCH children, the proportion of BRAF V600E mutational status was relatively high and related to multiple systems.
Citations
Citations to this article as recorded by
Sulfur dots/Au@Ag nanorods array-based polarized ECL sensor for the detection of thyroid cancer biomarker Zixuan Ding, Peilin Wang, Zhenrun Li, Yupeng Guo, Qiang Ma Talanta.2023; 265: 124925. CrossRef
Rare cases of lung adenocarcinoma (LUAD) with concomitant epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocation have been reported. However, their clonal and evolutional relationship remains unclear. We report a case of early-stage EGFR-mutated LUAD with a focal concomitant EGFR/ALK alteration. A 63-year-old male underwent lobectomy to remove a 1.9-cm-sized lung nodule, which was diagnosed with EGFR-mutated LUAD. ALK immunohistochemistry (IHC) showed focal positivity within the part of the tumor characterized by lepidic pattern, also confirmed by fluorescence in-situ hybridization (FISH). Targeted next-generation sequencing was performed separately on the ALK IHC/FISH-positive and -negative areas. EGFR L833V/L858R mutations were detected in both areas, whereas EML4 (echinoderm microtubule-associated protein-like 4)-ALK translocations was confirmed only in the ALK IHC/FISH-positive area, suggesting the divergence of an EGFR/ALK co-altered subclone from the original EGFR-mutant clone. Our study suggests that concurrent alterations of EGFR and ALK can arise via divergent tumor evolution, even in the relatively early phases of tumorigenesis.
Citations
Citations to this article as recorded by
Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps Yanhua Zuo, Guangyi Leng, Ping Leng Pathology and Oncology Research.2023;[Epub] CrossRef
Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma Zuwei Li, Minzhang Guo, Wanli Lin, Peiyuan Huang Archives of Medical Research.2023; 54(7): 102897. CrossRef
Big data analysis identified a telomere-related signature predicting the prognosis and drug sensitivity in lung adenocarcinoma Weiyi Zhang Medicine.2023; 102(46): e35526. CrossRef
The use of biomarkers to guide patient and therapy selection has gained much attention to increase the scope and complexity of targeted therapy options and immunotherapy. Clinical trials provide a basis for discovery of biomarkers, which can then aid in development of new drugs. To that end, samples from cancer patients, including DNA, RNA, protein, and the metabolome isolated from cancer tissues and blood or urine, are analyzed in various ways to identify relevant biomarkers. In conjunction with nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided biomarker assays relying on protein-based immunohistochemistry play a pivotal role in cancer care. In this review, we discuss the current knowledge regarding DNA and protein biomarkers for cancer immunotherapy
Citations
Citations to this article as recorded by
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer Moonsik Kim, Ji Yun Jeong, An Na Seo Diagnostics.2023; 13(17): 2782. CrossRef
Background Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC.
Methods Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated.
Results Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035).
Conclusions Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.
Citations
Citations to this article as recorded by
Multiple approaches revealed MGc80‐3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line Fang Cao, Hao Sun, Zhenli Yang, Yanhua Bai, Xiao Hu, Yuhong Hou, Xiaocui Bian, Yuqin Liu International Journal of Cancer.2024; 154(1): 155. CrossRef
In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis? Ikuko Sakamoto, Keiko Kagami, Takahiro Nozaki, Yosuke Hirotsu, Kenji Amemiya, Toshio Oyama, Masao Omata American Journal of Surgical Pathology.2024; 48(3): 374. CrossRef
CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function Carolina Pires, Inês J. Marques, Mariana Valério, Ana Saramago, Paulo E. Santo, Sandra Santos, Margarida Silva, Margarida M. Moura, João Matos, Teresa Pereira, Rafael Cabrera, Diana Lousa, Valeriano Leite, Tiago M. Bandeiras, João B. Vicente, Branca M. Ca Journal of Biological Chemistry.2024; 300(3): 105767. CrossRef
The spectrum of TP53 mutations in Rwandan patients with gastric cancer Augustin Nzitakera, Jean Bosco Surwumwe, Ella Larissa Ndoricyimpaye, Schifra Uwamungu, Delphine Uwamariya, Felix Manirakiza, Marie Claire Ndayisaba, Gervais Ntakirutimana, Benoit Seminega, Vincent Dusabejambo, Eric Rutaganda, Placide Kamali, François Ngab Genes and Environment.2024;[Epub] CrossRef
Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis Qunxian Rao, Jianwei Liao, Yangyang Li, Xin Zhang, Guocai Xu, Changbin Zhu, Shengya Tian, Qiuhong Chen, Hui Zhou, Bingzhong Zhang Cancer Medicine.2023; 12(5): 5409. CrossRef
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer Kenji Morimoto, Tadaaki Yamada, Ryo Sawada, Koichi Azuma, Yasuhiro Goto, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda, Osamu Hiranuma, Isao Hasegawa, Satomi Tanaka, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Y Cancer Immunology, Immunotherapy.2023; 72(6): 1699. CrossRef
Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis Barbara Brunetti, Dario de Biase, Giulia Dellapina, Luisa Vera Muscatello, Francesco Ingravalle, Giorgia Tura, Barbara Bacci Animals.2023; 13(5): 899. CrossRef
Mesonephric‐like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric‐like carcinosarcomas Jelena Mirkovic, Ekaterina Olkhov‐Mitsel, Yutaka Amemiya, Maysa Al‐Hussaini, Sharon Nofech‐Mozes, Bojana Djordjevic, Rachel Kupets, Arun Seth, W Glenn McCluggage Histopathology.2023; 82(7): 978. CrossRef
Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea Miseon Lee, Uiree Jo, Joon Seon Song, Youn Soo Lee, Chang Gok Woo, Dong-Hoon Kim, Jung Yeon Kim, Sun Och Yoon, Kyung-Ja Cho Journal of Pathology and Translational Medicine.2023; 57(3): 166. CrossRef
P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation Isabel Trias, Adela Saco, Lorena Marimon, Ricardo López del Campo, Carolina Manzotti, Oriol Ordi, Marta del Pino, Francisco M. Pérez, Naiara Vega, Silvia Alós, Antonio Martínez, Leonardo Rodriguez-Carunchio, Oscar Reig, Pedro Jares, Cristina Teixido, Tare Cancers.2023; 15(10): 2719. CrossRef
p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma Elisa Boldrin, Maria Assunta Piano, Francesco Bernaudo, Rita Alfieri, Maria Raffaella Biasin, Isabella Monia Montagner, Alice Volpato, Genny Mattara, Francesco Lamacchia, Giovanna Magni, Antonio Rosato, Antonio Scapinello, Pierluigi Pilati, Matteo Curtare Cancers.2023; 15(10): 2783. CrossRef
Genomic profiling of dedifferentiated endometrial carcinomas arising in the background of high‐grade carcinoma: a targeted next‐generation sequencing study Ekaterina Olkhov‐Mitsel, Aurelia Busca, Carlos Parra‐Herran, Yutaka Amemiya, Sharon Nofech‐Mozes, Bojana Djordjevic, Marisa R Nucci, Arun Seth, Jelena Mirkovic Histopathology.2023; 83(3): 366. CrossRef
Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma
Gizem Issin, İlyas Sayar, Fatih Demir, İrem Güvendir Bakkaloğlu, Mehmet Gamsizkan, Zeliha Yildiz, Ismail Yilmaz, Sevilay Akalp Özmen, Diren Vuslat Çağatay, Itır Ebru Zemheri, Murat Demiriz, Armağan Günal Journal of Environmental Pathology, Toxicology and Oncology.2023; 42(4): 1. CrossRef
Clinicopathologic and Molecular Characterization of Anorectal Neuroendocrine Carcinomas Reveals Human Papillomavirus, p53, and c-Myc as Alternative Mechanisms of Carcinogenesis Allison J. Cox, William E. Crowe, Qi Yang, Bin Zhang, Zoltán N. Oltvai, Xiaoyan Liao Modern Pathology.2023; 36(11): 100295. CrossRef
Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features Giovanna Giordano, Elena Ferioli, Debora Guareschi, Alessandro Tafuni Cancers.2023; 15(21): 5155. CrossRef
Characterization on the oncogenic effect of the missense mutations of p53 via machine learning Qisheng Pan, Stephanie Portelli, Thanh Binh Nguyen, David B Ascher Briefings in Bioinformatics.2023;[Epub] CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee Radiology.2022; 302(1): 129. CrossRef
Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex Shih-Chiang Huang, Kuang-Hua Chen, Kwai-Fong Ng, I-Chieh Lin, Yi-Chun Chao, Ta-Sen Yeh, Huei-Chieh Chuang, Tse-Ching Chen Virchows Archiv.2022; 480(4): 771. CrossRef
Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach Muxing Kang, Xiaojing Ma, Jifei Shi, Guofeng Chen, Xiaoli Jin, Jun Wang, Lele Lin, Zhiwei Wu, Kaibo Chen, Jinghong Xu, Pintong Huang, Jian Chen Translational Oncology.2022; 19: 101380. CrossRef
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status Anthony C Wood, Yonghong Zhang, Qianxing Mo, Ling Cen, Jacques Fontaine, Sarah E Hoffe, Jessica Frakes, Sean P Dineen, Jose M Pimiento, Christine M Walko, Rutika Mehta The Oncologist.2022; 27(4): 307. CrossRef
Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade Yangyang Wang, Bingfeng Huang, Qihan Fu, Jianing Wang, Mao Ye, Manyi Hu, Kai Qu, Kai Liu, Xiao Hu, Shumei Wei, Ke Sun, Wenbo Xiao, Bo Zhang, Haijun Li, Jingsong Li, Qi Zhang, Tingbo Liang Annals of Surgical Oncology.2022; 29(12): 7619. CrossRef
Expression of SASP, DNA Damage Response, and Cell Proliferation Factors in Early Gastric Neoplastic Lesions: Correlations and Clinical Significance Li Liang, Yijie Chai, Fei Chai, Haijing Liu, Ningning Ma, Hong Zhang, Shuang Zhang, Lin Nong, Ting Li, Bo Zhang Pathology and Oncology Research.2022;[Epub] CrossRef
Systems biology and OMIC data integration to understand gastrointestinal cancers Iasmin Moreira Costa Bispo, Henry Paul Granger, Palloma Porto Almeida, Patricia Belini Nishiyama, Leandro Martins de Freitas World Journal of Clinical Oncology.2022; 13(10): 762. CrossRef
MicroRNA-552 expression in colorectal cancer and its clinicopathological significance Joon Im, Soo Kyung Nam, Hye Seung Lee Journal of Pathology and Translational Medicine.2021; 55(2): 125. CrossRef
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study Ki Wook Kim, Nayoung Kim, Yonghoon Choi, Won Seok Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Young Suk Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Gastric Cancer.2021; 24(4): 844. CrossRef
The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Min Kyung Cho, Pill Sun Paik, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon, Elda Tagliabue PLOS ONE.2021; 16(5): e0250986. CrossRef
Morules, or morule-like features, can be identified in benign and malignant lesions in various organs. Morular features are unusual in pulmonary adenocarcinoma cases with only 26 cases reported to date. Here, we describe two cases of pulmonary adenocarcinoma with morule-like features in Korean women. One patient had a non-mucinous-type adenocarcinoma in situ and the other had an acinarpredominant adenocarcinoma with a micropapillary component. Both patients showed multiple intra-alveolar, nodular, whorled proliferative foci composed of atypical spindle cells with eosinophilic cytoplasm. Targeted next-generation sequencing was performed on DNA extracted from formalin-fixed paraffin-embedded samples of the tumors. Results showed unusual epidermal growth factor receptor (EGFR) mutations, which are associated with drug resistance to EGFR tyrosine kinase inhibitors, revealing the importance of identifying morule-like features in pulmonary adenocarcinoma and the need for additional study, since there are few reported cases.
Citations
Citations to this article as recorded by
Pulmonary adenocarcinoma in situ with morule - like components: A surgical case report Mitsuteru Yosida, Mitsuru Tomita, Naoya Kawakita, Teruki Shimizu, Ryou Yamada, Hiromitsu Takizawa, Hisanori Uehara Respiratory Medicine Case Reports.2024; 48: 102008. CrossRef
Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components Li-Li Wang, Li Ding, Peng Zhao, Jing-Jing Guan, Xiao-Bin Ji, Xiao-Li Zhou, Shi-Hong Shao, Yu-Wei Zou, Wei-Wei Fu, Dong-Liang Lin, Dong Pan Disease Markers.2021; 2021: 1. CrossRef
Background BRAF mutation has been recognized as an important biomarker of colorectal cancer (CRC) for targeted therapy and prognosis prediction. However, sequencing for every CRC case is not cost-effective. An antibody specific for BRAF V600E mutant protein has been introduced, and we thus examined the utility of BRAF VE1 immunohistochemistry for evaluating BRAF mutations in CRC.
Methods Fifty-one BRAF-mutated CRCs and 100 age and sexmatched BRAF wild-type CRCs between 2005 and 2015 were selected from the archives of Asan Medical Center. Tissue microarrays were constructed and stained with BRAF VE1 antibody.
Results Forty-nine of the 51 BRAF-mutant CRCs (96.1%) showed more than moderate cytoplasmic staining, except for two weakly stained cases. Six of 100 BRAF wild-type cases also stained positive with BRAF VE1 antibody; four stained weakly and two stained moderately. Normal colonic crypts showed nonspecific weak staining, and a few CRC cases exhibited moderate nuclear reactivity (3 BRAF-mutant and 10 BRAF wild-type cases). BRAF-mutated CRC patients had higher pathologic stages and worse survival than BRAF wild-type patients.
Conclusions BRAF VE1 immunohistochemistry showed high sensitivity and specificity, but occasional nonspecific staining in tumor cell nuclei and normal colonic crypts may limit their routine clinical use. Thus, BRAF VE1 immunohistochemistry may be a useful screening tool for BRAF V600E mutation in CRCs, provided that additional sequencing studies can be done to confirm the mutation in BRAF VE1 antibody-positive cases.
Citations
Citations to this article as recorded by
Immunohistochemistry as a Surrogate Marker of Underlying Molecular Derangements in Sporadic Colorectal Carcinoma in Children – A Series of Three Cases Priyanka Maity, Aniket Halder, Ranajoy Ghosh, Uttara Chatterjee, Shibsankar Barman, Ruchirendra Sarkar Fetal and Pediatric Pathology.2022; 41(1): 98. CrossRef
Risk assessment and genetic counseling for Lynch syndrome – Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Spring Holter, Michael J. Hall, Heather Hampel, Kory Jasperson, Sonia S. Kupfer, Joy Larsen Haidle, Maureen E. Mork, Selvi Palaniapppan, Leigha Senter, Elena M. Stoffel, Scott M. Weissman, Matthew B. Yurgelun Journal of Genetic Counseling.2022; 31(3): 568. CrossRef
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review Rogelio González-González, Sandra López-Verdín, Jesús Lavalle-Carrasco, Nelly Molina-Frechero, Mario Isiordia-Espinoza, Ramón G Carreón-Burciaga, Ronell Bologna-Molina World Journal of Clinical Oncology.2020; 11(1): 31. CrossRef
Genetic and histopathological analysis of a case of primary intraosseous carcinoma, NOS with features of both ameloblastic carcinoma and squamous cell carcinoma Akane Yukimori, Maiko Tsuchiya, Akane Wada, Yasuyuki Michi, Kou Kayamori, Kei Sakamoto, Tohru Ikeda World Journal of Surgical Oncology.2020;[Epub] CrossRef
Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, Byoung Chul Cho, Eun Kyung Cho, Young Joo Min, Ki Hyeong Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Tae Jung Kim, Ho Yun Lee, Hojoong Kim, Kyung-Jong Lee, Myung-Ju Ahn
J Pathol Transl Med. 2018;52(3):148-156. Published online March 26, 2018
Background Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC.
Methods DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2.
Results The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study.
Conclusions These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.
Citations
Citations to this article as recorded by
PTEN, PTENP1, microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics Glena Travis, Eileen M. McGowan, Ann M. Simpson, Deborah J. Marsh, Najah T. Nassif Cancers.2023; 15(20): 4954. CrossRef
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis Barbara Melosky, Kato Kambartel, Maik Häntschel, Margherita Bennetts, Dana J. Nickens, Julia Brinkmann, Antonin Kayser, Michael Moran, Federico Cappuzzo Molecular Diagnosis & Therapy.2022; 26(1): 7. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Suitability of transbronchial brushing cytology specimens for next‐generation sequencing in peripheral lung cancer Naoki Furuya, Shingo Matsumoto, Kazutaka Kakinuma, Kei Morikawa, Takeo Inoue, Hisashi Saji, Koichi Goto, Masamichi Mineshita Cancer Science.2021; 112(1): 380. CrossRef
KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway Yitong Xu, Chenglong Wang, Xizi Jiang, Yao Zhang, Hongbo Su, Jun Jiang, Hongjiu Ren, Xueshan Qiu Cell Death & Disease.2021;[Epub] CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion Quincy S. Chu Therapeutic Advances in Medical Oncology.2020; 12: 175883591989575. CrossRef
Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients
Hengrui Liang, Caichen Li, Yi Zhao, Shen Zhao, Jun Huang, Xiuyu Cai, Bo Cheng, Shan Xiong, Jianfu Li, Wei Wang, Changbin Zhu, Weiwei Li, Jianxing He, Wenhua Liang Cancer Management and Research.2020; Volume 12: 8653. CrossRef
Prognostic role of Rab27A and Rab27B expression in patients with non‐small cell lung carcinoma Hyun Min Koh, Dae Hyun Song Thoracic Cancer.2019; 10(2): 143. CrossRef
PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1 Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim Thoracic Cancer.2019; 10(1): 103. CrossRef
Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer Hersh A. Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, Wakkas Fadhil, Narmeen S. Ahmad, Susan D. Richman, Mohammad Ilyas Molecular Diagnosis & Therapy.2019; 23(3): 383. CrossRef
Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing Hidenori Kage, Shinji Kohsaka, Aya Shinozaki‐Ushiku, Yoshihisa Hiraishi, Jiro Sato, Kazuhiro Nagayama, Tetsuo Ushiku, Daiya Takai, Jun Nakajima, Kiyoshi Miyagawa, Hiroyuki Aburatani, Hiroyuki Mano, Takahide Nagase Cancer Science.2019; 110(8): 2652. CrossRef
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around Anastasios Gkountakos, Giulia Sartori, Italia Falcone, Geny Piro, Ludovica Ciuffreda, Carmine Carbone, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Michele Milella, Rafael Rosell, Vincenzo Corbo, Sara Pilotto Cancers.2019; 11(8): 1141. CrossRef
The World Health Organization (WHO) classification of central nervous system (CNS) tumors was revised in 2016 with a basis on the integrated diagnosis of molecular genetics. We herein provide the guidelines for using molecular genetic tests in routine pathological practice for an accurate diagnosis and appropriate management. While astrocytomas and IDH-mutant (secondary) glioblastomas are characterized by the mutational status of IDH, TP53, and ATRX, oligodendrogliomas have a 1p/19q codeletion and mutations in IDH, CIC, FUBP1, and the promoter region of telomerase reverse transcriptase (TERTp). IDH-wildtype (primary) glioblastomas typically lack mutations in IDH, but are characterized by copy number variations of EGFR, PTEN, CDKN2A/B, PDGFRA, and NF1 as well as mutations of TERTp. High-grade pediatric gliomas differ from those of adult gliomas, consisting of mutations in H3F3A, ATRX, and DAXX, but not in IDH genes. In contrast, well-circumscribed low-grade neuroepithelial tumors in children, such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and ganglioglioma, often have mutations or activating rearrangements in the BRAF, FGFR1, and MYB genes. Other CNS tumors, such as ependymomas, neuronal and glioneuronal tumors, embryonal tumors, meningothelial, and other mesenchymal tumors have important genetic alterations, many of which are diagnostic, prognostic, and predictive markers and therapeutic targets. Therefore, the neuropathological evaluation of brain tumors is increasingly dependent on molecular genetic tests for proper classification, prediction of biological behavior and patient management. Identifying these gene abnormalities requires cost-effective and high-throughput testing, such as next-generation sequencing. Overall, this paper reviews the global guidelines and diagnostic algorithms for molecular genetic testing of brain tumors.
Citations
Citations to this article as recorded by
PTEN regulates expression of its pseudogene in glioblastoma cells in DNA methylation-dependent manner Tatyana F. Kovalenko, Bhupender Yadav, Ksenia S. Anufrieva, Tatyana D. Larionova, Tatiana E. Aksinina, Yaroslav A. Latyshev, Soniya Bastola, Michail I. Shakhparonov, Amit Kumar Pandey, Marat S. Pavlyukov Biochimie.2024; 219: 74. CrossRef
Central neurocytoma exhibits radial glial cell signatures with FGFR3 hypomethylation and overexpression Yeajina Lee, Tamrin Chowdhury, Sojin Kim, Hyeon Jong Yu, Kyung-Min Kim, Ho Kang, Min-Sung Kim, Jin Wook Kim, Yong-Hwy Kim, So Young Ji, Kihwan Hwang, Jung Ho Han, Jinha Hwang, Seong-Keun Yoo, Kyu Sang Lee, Gheeyoung Choe, Jae-Kyung Won, Sung-Hye Park, Yon Experimental & Molecular Medicine.2024;[Epub] CrossRef
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario Marina Ferreira Candido, Mariana Medeiros, Luciana Chain Veronez, David Bastos, Karla Laissa Oliveira, Julia Alejandra Pezuk, Elvis Terci Valera, María Sol Brassesco Pharmaceutics.2023; 15(2): 664. CrossRef
BrainBase: a curated knowledgebase for brain diseases Lin Liu, Yang Zhang, Guangyi Niu, Qianpeng Li, Zhao Li, Tongtong Zhu, Changrui Feng, Xiaonan Liu, Yuansheng Zhang, Tianyi Xu, Ruru Chen, Xufei Teng, Rongqin Zhang, Dong Zou, Lina Ma, Zhang Zhang Nucleic Acids Research.2022; 50(D1): D1131. CrossRef
A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations Kuan-Ta Ho, Pei-Fan Chen, Jian-Ying Chuang, Po-Wu Gean, Yuan-Shuo Hsueh Life Sciences.2022; 288: 120176. CrossRef
Bicentric validation of the navigated transcranial magnetic stimulation motor risk stratification model Tizian Rosenstock, Levin Häni, Ulrike Grittner, Nicolas Schlinkmann, Meltem Ivren, Heike Schneider, Andreas Raabe, Peter Vajkoczy, Kathleen Seidel, Thomas Picht Journal of Neurosurgery.2022; 136(4): 1194. CrossRef
Foramen magnum meningioma presented as cervical myelopathy in a pregnant COVID-19 patient: A case report Olivia Josephine Wijaya, Djohan Ardiansyah Annals of Medicine and Surgery.2022; 77: 103647. CrossRef
The telomere maintenance mechanism spectrum and its dynamics in gliomas Sojin Kim, Tamrin Chowdhury, Hyeon Jong Yu, Jee Ye Kahng, Chae Eun Lee, Seung Ah. Choi, Kyung-Min Kim, Ho Kang, Joo Ho Lee, Soon-Tae Lee, Jae-Kyung Won, Kyung Hyun Kim, Min-Sung Kim, Ji Yeoun Lee, Jin Wook Kim, Yong-Hwy Kim, Tae Min Kim, Seung Hong Choi, Genome Medicine.2022;[Epub] CrossRef
A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy Ernest Osei, Pascale Walters, Olivia Masella, Quinton Tennant, Amber Fishwick, Eugenia Dadzie, Anmol Bhangu, Johnson Darko Journal of Radiotherapy in Practice.2021; 20(1): 83. CrossRef
Use of a novel navigable tubular retractor system in 1826 minimally invasive parafascicular surgery (MIPS) cases involving deep-seated brain tumors, hemorrhages and malformations Martina M. Cartwright, Penny Sekerak, Joseph Mark, Julian Bailes Interdisciplinary Neurosurgery.2021; 23: 100919. CrossRef
Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond S. Daisy Precilla, Shreyas S. Kuduvalli, Anitha Thirugnanasambandhar Sivasubramanian Cell Biology International.2021; 45(1): 18. CrossRef
Sequencing of a central nervous system tumor demonstrates cancer transmission in an organ transplant Marie-Claude Gingras, Aniko Sabo, Maria Cardenas, Abbas Rana, Sadhna Dhingra, Qingchang Meng, Jianhong Hu, Donna M Muzny, Harshavardhan Doddapaneni, Lesette Perez, Viktoriya Korchina, Caitlin Nessner, Xiuping Liu, Hsu Chao, John Goss, Richard A Gibbs Life Science Alliance.2021; 4(9): e202000941. CrossRef
Radiogenomics of Gliomas Chaitra Badve, Sangam Kanekar Radiologic Clinics of North America.2021; 59(3): 441. CrossRef
Chemical analysis of the human brain by imaging mass spectrometry Akhila Ajith, Yeswanth Sthanikam, Shibdas Banerjee The Analyst.2021; 146(18): 5451. CrossRef
Correlation between Stage and Histopathological Features and Clinical Outcomes in Patients with Glioma Tumors Andre Lona, Alfansuri Kadri, Irina Kemala Nasution Open Access Macedonian Journal of Medical Sciences.2021; 9(T3): 262. CrossRef
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi Cancers.2021; 13(4): 758. CrossRef
Discovery of clinically relevant fusions in pediatric cancer Stephanie LaHaye, James R. Fitch, Kyle J. Voytovich, Adam C. Herman, Benjamin J. Kelly, Grant E. Lammi, Jeremy A. Arbesfeld, Saranga Wijeratne, Samuel J. Franklin, Kathleen M. Schieffer, Natalie Bir, Sean D. McGrath, Anthony R. Miller, Amy Wetzel, Katheri BMC Genomics.2021;[Epub] CrossRef
Clinicopathological correlation of glioma patients with respect to immunohistochemistry markers: A prospective study of 115 patients in a Tertiary Care Hospital in North India Gitanshu Dahuja, Ashok Gupta, Arpita Jindal, Gaurav Jain, Santosh Sharma, Arvind Kumar Asian Journal of Neurosurgery.2021; 16(04): 732. CrossRef
Role of Extracellular Vesicles in Glioma Progression: Deciphering Cellular Biological Processes to Clinical Applications Rashmi Rana, Shikha Joon, Kirti Chauhan, Vaishnavi Rathi, Nirmal Kumar Ganguly, Chandni Kumari, Dharmendra Kumar Yadav Current Topics in Medicinal Chemistry.2021; 21(8): 696. CrossRef
A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know P. D. Delgado-López, P. Saiz-López, R. Gargini, E. Sola-Vendrell, S. Tejada Clinical and Translational Oncology.2020; 22(11): 1909. CrossRef
Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors Natalia Magdalena Chrzanowska, Janusz Kowalewski, Marzena Anna Lewandowska Molecules.2020; 25(8): 1864. CrossRef
From Banding to BAM Files Adrian M. Dubuc Surgical Pathology Clinics.2020; 13(2): 343. CrossRef
Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing Ejaz Butt, Sabra Alyami, Tahani Nageeti, Muhammad Saeed, Khalid AlQuthami, Abdellatif Bouazzaoui, Mohammad Athar, Zainularifeen Abduljaleel, Faisal Al-Allaf, Mohiuddin Taher F1000Research.2020; 8: 613. CrossRef
Assessment of the non-linear optical behavior of cells for discrimination between normal and malignant glial cells Soraya Emamgholizadeh Minaei, Alireza Ghader, Ali Abbasian Ardakani, Samideh Khoei, Mohammad Hosein Majles Ara Laser Physics.2020; 30(12): 125601. CrossRef
Mutation profiling of anaplastic ependymoma grade III by Ion Proton next generation DNA sequencing Muhammad Butt, Sabra Alyami, Tahani Nageeti, Muhammad Saeed, Khalid AlQuthami, Abdellatif Bouazzaoui, Mohammad Athar, Zainularifeen Abduljaleel, Faisal Al-Allaf, Mohiuddin Taher F1000Research.2019; 8: 613. CrossRef
A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549–BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas David Bret, Valentin Chappuis, Delphine Poncet, François Ducray, Karen Silva, Fabrice Mion, Alexandre Vasiljevic, Carole Ferraro-Peyret, Carmine Mottolese, Pierre Leblond, Mathieu Gabut, Didier Frappaz, Nathalie Streichenberger, David Meyronet, Pierre-Pau Molecular Diagnosis & Therapy.2019; 23(4): 537. CrossRef
A PTPmu Biomarker is Associated with Increased Survival in Gliomas Mette L. Johansen, Jason Vincent, Haley Gittleman, Sonya E. L. Craig, Marta Couce, Andrew E. Sloan, Jill S. Barnholtz-Sloan, Susann M. Brady-Kalnay International Journal of Molecular Sciences.2019; 20(10): 2372. CrossRef
ATRX Mutations in Pineal Parenchymal Tumors of Intermediate Differentiation Haydee Martínez, Michelle Nagurney, Zi-Xuan Wang, Charles G Eberhart, Christopher M Heaphy, Mark T Curtis, Fausto J Rodriguez Journal of Neuropathology & Experimental Neurology.2019; 78(8): 703. CrossRef
The role of fibroblast growth factors and their receptors in gliomas: the mutations involved Vasiliki Georgiou, Vasiliki Gkretsi Reviews in the Neurosciences.2019; 30(5): 543. CrossRef
The Role of Next Generation Sequencing in Diagnosis of Brain Tumors: A Review Study Sadegh Shirian, Yahya Daneshbod, Saranaz Jangjoo, Amir Ghaemi, Arash Goodarzi, Maryam Ghavideldarestani, Ahmad Emadi, Arman Ai, Akbar Ahmadi, Jafar Ai Archives of Neuroscience.2019;[Epub] CrossRef
Applied Precision Cancer Medicine in Neuro-Oncology H. Taghizadeh, L. Müllauer, J. Furtner, J. A. Hainfellner, C. Marosi, M. Preusser, G. W. Prager Scientific Reports.2019;[Epub] CrossRef
Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas Joshua Loewenstern, John Rutland, Corey Gill, Hanane Arib, Margaret Pain, Melissa Umphlett, Yayoi Kinoshita, Russell McBride, Michael Donovan, Robert Sebra, Joshua Bederson, Mary Fowkes, Raj Shrivastava Oncotarget.2019; 10(37): 3506. CrossRef
Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton Mohiuddin Taher, Amal Hassan, Muhammad Saeed, Raid Jastania, Tahani Nageeti, Hisham Alkhalidi, Ghida Dairi, Zainularifeen Abduljaleel, Mohammad Athar, Abdellatif Bouazzaoui, Wafa El‑Bjeirami, Faisal Al‑Allaf Oncology Letters.2019;[Epub] CrossRef
Pure mechanistic analysis of additive neuroprotective effects between baicalin and jasminoidin in ischemic stroke mice Peng-qian Wang, Qiong Liu, Wen-juan Xu, Ya-nan Yu, Ying-ying Zhang, Bing Li, Jun Liu, Zhong Wang Acta Pharmacologica Sinica.2018; 39(6): 961. CrossRef
The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma Yumin Chung, Young Chan Wi, Yeseul Kim, Seong Sik Bang, Jung-Ho Yang, Kiseok Jang, Kyueng-Whan Min, Seung Sam Paik Journal of Pathology and Translational Medicine.2018; 52(1): 37. CrossRef
Primary brain tumours in adults Sarah Lapointe, Arie Perry, Nicholas A Butowski The Lancet.2018; 392(10145): 432. CrossRef
Epidemiology and Overview of Gliomas Mary Elizabeth Davis Seminars in Oncology Nursing.2018; 34(5): 420. CrossRef
Toward Precision Medicine: Promising Areas of Research in Glioma Mary Elizabeth Davis, Dana Bossert, Malbora Manne Seminars in Oncology Nursing.2018; 34(5): 569. CrossRef
Molecular Basis of Pediatric Brain Tumors Alexia Klonou, Christina Piperi, Antonios N. Gargalionis, Athanasios G. Papavassiliou NeuroMolecular Medicine.2017; 19(2-3): 256. CrossRef